[en] Background: Neonatal screening is the first action necessary to identify children with sickle cell disease (SCD) and thus ensure their care. Using rapid tests to give an immediate result to families is a new resilient approach of great interest. These two aspects are essential for establishing an adequate health policy for this disease. This study was undertaken in Kisangani to update the current incidence of neonatal SCD. Methods: Heel prick blood samples of 1432 babies born from different racial groups of parents living in Kisangani were collected at birth and screened using a point of care test, i.e. the HemoTypeSCTM. Results: The incidence at birth was 2.2% (n = 31; 95% CI: [1.5%−3.1%]) for HbSS homozygosity and 21% (n = 303; 95% CI: [19%−23%]) for HbAS heterozygosity. Compared to a previous study in 2010; the incidence at the birth of the HbSS form has doubled, while that of the heterozygous form HbAS remained almost unchanged. The inter-ethnic incidence of HbSS among the five top-represented ethnic groups was significant (<0.001). Conclusion: The prevalence of homozygote form has doubled compared to the 0.96% reported in 2010. Setting up a neonatal screening program and an awareness unit is necessary to assess the need for care services correctly.
Disciplines :
Genetics & genetic processes
Author, co-author :
Kasai, Emmanuel Tebandite ; Department of Pediatrics, Faculty of Medicine and Pharmacy, University of Kisangani, Kisangani, Democratic Republic Congo
Gulbis, Béatrice; Department of Clinical Chemistry, Erasmus Hospital, Université Libre de Bruxelles, Brussels, Belgium
Ntukamunda, Justin Kadima; Department of Pharmacy, Faculty of Medicine and Pharmacy, University of Kisangani, Kisangani, Democratic Republic Congo
Bours, Vincent ; Université de Liège - ULiège > GIGA > GIGA Cancer - Human Genetics
Batina Agasa, Salomon; Department of Internal Medicine, Faculty of Medicine and Pharmacy, University of Kisangani, Kisangani, Democratic Republic Congo
Marini Djang'Eing'A, Roland ; Université de Liège - ULiège > Département de pharmacie > Chimie analytique ; Department of Clinical Chemistry, Erasmus Hospital, Université Libre de Bruxelles, Brussels, Belgium
Boemer, François ; Université de Liège - ULiège > Département de pharmacie > Chimie médicale
Katenga Bosunga, Gedeon; Department of Obstetrics and Gynecology, Kisangani University Clinics, University of Kisangani, Kisangani, Democratic Republic Congo
Ngbonda Dauly, Nestor; Department of Pediatrics, Faculty of Medicine and Pharmacy, University of Kisangani, Kisangani, Democratic Republic Congo
Sokoni Vutseme, La Joie; Department of Anthropology, Faculty of Social, Administrative and Political Sciences, University of Kisangani, Kisangani, Democratic Republic Congo
Boso Mokili, Bosco; Faculty of Medicine and Pharmacy, University of Kisangani, Kisangani, Democratic Republic Congo
Alworong’a Opara, Jean Pierre; Department of Pediatrics, Faculty of Medicine and Pharmacy, University of Kisangani, Kisangani, Democratic Republic Congo
Language :
English
Title :
Newborn screening for sickle cell disease in Kisangani, Democratic Republic of the Congo: an update
The authors are grateful to the Academy of Research and Higher Education of the Belgian Development Cooperation for supporting the PRD-DREPAKIS project and the Synergie Save Drepachild project. The authors are also grateful to all the health actors who helped with the data collection.
Weatherall DJ. The inherited diseases of hemoglobin are an emerging global health burden. Blood. 2010; 115: 4331–4336. DOI: 10.1182/blood-2010-01-251348.
Piel FB, Patil AP, Howes RE, et al. Global epidemiology of sickle haemoglobin in neonates: A contemporary geostatistical model-based map and population estimates. Lancet. 2013; 381: 142–151. DOI: 10.1016/S0140-6736(12)61229-X.
Mengnjo MK, Kamtchum-Tatuene J, Nicastro N, et al. Complications of sickle cell disease in Africa: protocol for a systematic review. Br Med J. 2016; 6: e012981. DOI: 10.1136/bmjopen-2016-012981.
Kasai ET, Opara JPA, Kadima JN, et al. Overview of current progress and challenges in diagnosis, and management of pediatric sickle cell disease in democratic republic of the Congo. Hematology. 2022; 1: 132–140. DOI: 10.1080/16078454.2021.2023399.
Lindenau JD, Wagner SC, Castro SM, et al. The effects of old and recent migration waves in the distribution of HBB* S globin gene haplotypes. Genet Mol Biol. 2016; 39: 515–523. DOI: 10.1590/1678-4685-gmb-2016-0032.
Dokekias AE, Gokaba LTO, Louokdom JS, et al. Neonatal screening for sickle cell disease in Congo. Anemia. 2022; 6:Article ID 9970315. DOI: 10.1155/2022/9970315.
Munyanganizi R, Cotton F, Vertongen F, et al. Red blood cell disorders in Rwandese neonates: screening for sickle cell disease and glucose-6-phosphate dehydrogenase deficiency. J Med Screen. 2006; 13: 129–131.
McGann PT, Ferris MG, Ramamurthy U, et al. A prospective newborn screening and treatment program for sickle cell anemia in Luanda. Angola Am J Hematol. 2013; 88: 984–989. DOI: 10.1002/ajh.23578.
Abdala KA, Shindano ME, Mbongi D, et al. Dépistage hospitalier de la drépanocytose en République Démocratique du Congo (RDC) par HemoTypeSC: cas de la ville de Kindu. Pan African Med J. 2022; 41: 134. DOI: 10.11604/pamj.2022.41.134.30187.
Tebandite K, Muyobela K, Lusamaki M, et al. Effect of TB therapy on the health and nutritional status of infants aged 6 months to 5 years diagnosed with latent TB. J Tuberculosis Res. 2018; 6: 239–250. DOI: 10.4236/jtr.2018.64022.
Agasa B, Bosunga K, Opara A, et al. Prevalence of sickle cell disease in a northeastern region of the democratic Republic of Congo: what impact on transfusion policy? British blood transfusion society. Transfus Med. 2010; 20: 62–65. DOI: 10.1111/j.1365-3148.2009.00943.x.
Kasai ET, Opara JPA, Agasa SB, et al. Acceptabilité du Dépistage néonatal de la drépanocytose au cours de la Pandémie au COVID-19 à Kisangani, en République Démocratique du Congo. Pan African Journal of Medicine. 2020; 37: 299. DOI: 10.11604/pamj.2020.37.299.26654.
Kasai ET, Boemer F, Djang’eing’a RM, et al. Systematic screening of Neo- natal sickle cell disease with HemoTypeSCTM Kit-test: case study and literature review. Open Journal of Blood Diseases. 2020; 10: 12–21. DOI: 10.4236/ojbd.2020.101002.
Neema-UfoyMungu Y, Juakali-Sihalikyolo JJ, Djang’eing’a RM, et al. Performance of sickle SCAN® in the screening of sickle cell disease in Kisangani pregnant women and attitude towards results. Open J Blood Dis. 2020; 10: 23–36. DOI: 10.4236/ojbd.2020.102003.
Kasai ET, Kadima JN, Opara JPA, et al. Pairing parents and offspring’s HemoTypeSC test to validate results and confirm sickle cell pedigree: case study in Kisangani, Democratic Republic of the Congo. Hematology. 2022; 27 (1): 853–859. DOI: 10.1080/16078454.2022.2107351.
Christopher H, Josephat E, Kaywanga F, et al. Potential of point of care tests for newborn screening for sickle cell disease: evaluation of HemotypeSC™ and sickle SCAN® in Tanzania. Int J Lab Hematol. 2022; 44: 959–965. DOI: 10.1111/ijlh.13929.
Olatunya OS, Albuquerque DM, Fagbamigbe AF, et al. Diagnostic accuracy of HemoTypeSC as a point-of-care testing device for sickle cell disease: findings from a southwestern State in Nigeria and implications for patient care in resource poor settings of sub-Saharan Africa. Global Pediatric Health. 2021; 8: 1–10. DOI: 10.1177/2333794X211016789.
Mukherjee MB, Colah RB, Mehta PR, et al. Multicenter evaluation of HemoTypeSC as a point-of-care sickle cell disease rapid diagnostic test for newborns and adults across India. Am J Clin Pathol. 2020; 153 (1): 82–87. DOI: 10.1093/ajcp/aqz108.
Boemer F, Cornet Y, Libioulle C, et al. 3-years’experience review of neonatal screening for hemoglobin disorders using tandem mass spectrometry. Clin Chim Acta. 2011; 412 (2011): 1476–1479. DOI: 10.1016/j.cca.2011.04.031.
Cuschieri S. The STROBE guidelines. Saudi J Anaesth. 2019; 13 (Suppl 1): S31–S34. DOI: 10.4103/sja.SJA_543_18.
Pare NI. Problématique du dépistage néonatal de la drépanocytose dans la ville de Kayes au Mali [Thèse]. Bamako: Université de Bamako-Faculté de Médecine et d’odontologie; 2021. [cited 2023 Feb 28]. Available at: https://bibliosante.ml.handle.
Shongo MYP, Mukuku O. Dépistage néonatal de la drépanocytose à Lubumbashi, République Démocratique du Congo. Rev L’Infirmier Congol. 2018; 2: 62–63.
Kanyunyu J. Ebola en RDC: les raisons de la méfiance face au vaccin. Consulté le 06 octobre 2020. [cited 2023 Feb 28]. Available at https://www.dw.com/fr/ebola-en-rdc-les-raisons-de-la-m%C3%A9fiance-face-au-vaccin/a-49902768.
Singa VB, Lungela SB. Facteurs déterminants les accouchements à domiciles dans la zone de sante de yahisuli, R. D. Congo « Risque et prévention ». IJRDO - J Health Sci Nursing. 2019; 4 (10): 42–57.
McGann PT. Time to invest in sickle cell anemia as a global health priority. Pediatrics. 2016; 137 (6): e20160348. DOI: 10.1542/peds.2016-0348.
Tshilolo L, Aissi LM, Lukusa D, et al. Neonatal screening for sickle cell anaemia in the Democratic Republic of the Congo: experience from a pioneer project on 31 204 newborns. J Clin Pathol. 2009; 62: 35–38. DOI: 10.1136/jcp.2008.058958.
Nankanja R, Kadhumbula S, Tagoola A, et al. HemoTypeSC demonstrates >99% field accuracy in a sickle cell disease screening initiative in children of southeastern Uganda. Am J Hematol. 2019; 94: E164–E166.
Ambrose EE, Makani J, Chami N, et al. High birth prevalence of sickle cell disease in Northwestern Tanzania. Pediatr Blood Cancer. 2018; 65 (1). DOI: 10.1002/pbc.26735.
Elgueroa E, Délicat-Loembeta LM, Rougerona V, et al. Malaria continues to select for sickle cell trait in Central Africa. Proc Natl Acad Sci. 2015; 12 (22): 7051–7054.
Likwela DL. Les généralités sur le Paludisme. [Thèse]. Kisangani: Université de Kisangani-Faculté de Médecine et de Pharmacie; 2011. Available at file:///C:/Users/utilisateur/Downloads/07Premierepartie.pdf consulté le 11/01/2022.
